Logo image of ACCD

ACCOLADE INC (ACCD) Stock Fundamental Analysis

NASDAQ:ACCD - Nasdaq - US00437E1029 - Common Stock - Currency: USD

7.02  -0.01 (-0.14%)

After market: 7.02 0 (0%)

Fundamental Rating

3

Overall ACCD gets a fundamental rating of 3 out of 10. We evaluated ACCD against 102 industry peers in the Health Care Providers & Services industry. While ACCD seems to be doing ok healthwise, there are quite some concerns on its profitability. ACCD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year ACCD has reported negative net income.
ACCD had a negative operating cash flow in the past year.
In the past 5 years ACCD always reported negative net income.
ACCD had a negative operating cash flow in each of the past 5 years.
ACCD Yearly Net Income VS EBIT VS OCF VS FCFACCD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

The Return On Assets of ACCD (-27.85%) is worse than 83.02% of its industry peers.
With a Return On Equity value of -57.60%, ACCD is not doing good in the industry: 72.64% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -27.85%
ROE -57.6%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACCD Yearly ROA, ROE, ROICACCD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

With a decent Gross Margin value of 48.15%, ACCD is doing good in the industry, outperforming 75.47% of the companies in the same industry.
ACCD's Gross Margin has improved in the last couple of years.
ACCD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.11%
GM growth 5Y5.22%
ACCD Yearly Profit, Operating, Gross MarginsACCD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

4

2. Health

2.1 Basic Checks

ACCD does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACCD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACCD Yearly Shares OutstandingACCD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M
ACCD Yearly Total Debt VS Total AssetsACCD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.06, we must say that ACCD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ACCD (-1.06) is worse than 82.08% of its industry peers.
A Debt/Equity ratio of 0.67 indicates that ACCD is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.67, ACCD perfoms like the industry average, outperforming 55.66% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Altman-Z -1.06
ROIC/WACCN/A
WACC7.47%
ACCD Yearly LT Debt VS Equity VS FCFACCD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

ACCD has a Current Ratio of 2.63. This indicates that ACCD is financially healthy and has no problem in meeting its short term obligations.
ACCD's Current ratio of 2.63 is amongst the best of the industry. ACCD outperforms 81.13% of its industry peers.
ACCD has a Quick Ratio of 2.63. This indicates that ACCD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ACCD (2.63) is better than 81.13% of its industry peers.
Industry RankSector Rank
Current Ratio 2.63
Quick Ratio 2.63
ACCD Yearly Current Assets VS Current LiabilitesACCD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

6

3. Growth

3.1 Past

ACCD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.76%, which is quite impressive.
Looking at the last year, ACCD shows a quite strong growth in Revenue. The Revenue has grown by 14.99% in the last year.
The Revenue has been growing by 34.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)35.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.71%
Revenue 1Y (TTM)14.99%
Revenue growth 3Y34.47%
Revenue growth 5Y34.31%
Sales Q2Q%5.73%

3.2 Future

The Earnings Per Share is expected to grow by 20.04% on average over the next years. This is a very strong growth
Based on estimates for the next years, ACCD will show a quite strong growth in Revenue. The Revenue will grow by 13.82% on average per year.
EPS Next Y-8.14%
EPS Next 2Y17.4%
EPS Next 3Y15.02%
EPS Next 5Y20.04%
Revenue Next Year13.05%
Revenue Next 2Y12.53%
Revenue Next 3Y12.5%
Revenue Next 5Y13.82%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ACCD Yearly Revenue VS EstimatesACCD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ACCD Yearly EPS VS EstimatesACCD Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -2 -4 -6

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACCD. In the last year negative earnings were reported.
Also next year ACCD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACCD Price Earnings VS Forward Price EarningsACCD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACCD Per share dataACCD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as ACCD's earnings are expected to grow with 15.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.4%
EPS Next 3Y15.02%

0

5. Dividend

5.1 Amount

No dividends for ACCD!.
Industry RankSector Rank
Dividend Yield N/A

ACCOLADE INC

NASDAQ:ACCD (4/7/2025, 8:11:12 PM)

After market: 7.02 0 (0%)

7.02

-0.01 (-0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)01-17 2025-01-17/bmo
Earnings (Next)04-23 2025-04-23/amc
Inst Owners82.6%
Inst Owner Change10.47%
Ins Owners3.24%
Ins Owner Change-121.34%
Market Cap575.57M
Analysts53.75
Price Target6.83 (-2.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.01%
Min EPS beat(2)32.78%
Max EPS beat(2)57.24%
EPS beat(4)3
Avg EPS beat(4)20.09%
Min EPS beat(4)-38.53%
Max EPS beat(4)57.24%
EPS beat(8)7
Avg EPS beat(8)20.01%
EPS beat(12)10
Avg EPS beat(12)12.6%
EPS beat(16)11
Avg EPS beat(16)2.19%
Revenue beat(2)0
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-2.56%
Max Revenue beat(2)-0.7%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-2.56%
Max Revenue beat(4)2.92%
Revenue beat(8)4
Avg Revenue beat(8)-0.07%
Revenue beat(12)8
Avg Revenue beat(12)0.64%
Revenue beat(16)12
Avg Revenue beat(16)1.56%
PT rev (1m)-3.17%
PT rev (3m)-6.66%
EPS NQ rev (1m)-35.39%
EPS NQ rev (3m)-17.28%
EPS NY rev (1m)-7.63%
EPS NY rev (3m)-53.12%
Revenue NQ rev (1m)1.92%
Revenue NQ rev (3m)1.8%
Revenue NY rev (1m)0.54%
Revenue NY rev (3m)0.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.29
P/FCF N/A
P/OCF N/A
P/B 1.84
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS5.45
BVpS3.82
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.85%
ROE -57.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.15%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.11%
GM growth 5Y5.22%
F-Score4
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.12%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.63
Quick Ratio 2.63
Altman-Z -1.06
F-Score4
WACC7.47%
ROIC/WACCN/A
Cap/Depr(3y)17.24%
Cap/Depr(5y)23.91%
Cap/Sales(3y)2.06%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.71%
EPS Next Y-8.14%
EPS Next 2Y17.4%
EPS Next 3Y15.02%
EPS Next 5Y20.04%
Revenue 1Y (TTM)14.99%
Revenue growth 3Y34.47%
Revenue growth 5Y34.31%
Sales Q2Q%5.73%
Revenue Next Year13.05%
Revenue Next 2Y12.53%
Revenue Next 3Y12.5%
Revenue Next 5Y13.82%
EBIT growth 1Y36.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year116.25%
EBIT Next 3Y36.45%
EBIT Next 5Y25.67%
FCF growth 1Y72.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.28%
OCF growth 3YN/A
OCF growth 5YN/A